- Home
- ONCO
ONCO
Onconetix Inc.
as of 03-10-2026 4:00pm EST
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CINCINNATI |
| Market Cap: | 2.3M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 539.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | -29.14 | EPS Growth: | -879.45 |
| 52 Week Low/High: | $0.05 - $7.65 | Next Earning Date: | N/A |
| Revenue: | $2,524,116 | Revenue Growth: | 4217.31% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.02 | Index: | N/A |
| Free Cash Flow: | -10524287.0 | FCF Growth: | N/A |
Compare ONCO vs Leading Stocks
See how ONCO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ONCO Onconetix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.